Ann S. Hamilton, PhD

Dr. Hamilton is a cancer epidemiologist with an interest in etiology of cancer as well as in cancer outcomes research. She has conducted several studies of prostate cancer survivors using cases obtained from the Los Angeles County SEER registry. Specifically, she was the Los Angeles PI for the Prostate Cancer Outcomes study which followed men for 15 years after diagnosis and was also the site PI for the CEASAR cohort which obtained treatment and outcome data for men diagnosed in 2011. In addition, she is leading the Los Angeles component of the PC Concept study which is designed to assess treatment related effects from newer prostate cancer treatment methods including focal therapy and SBRT. She has played a major role in analyzing the prostate patterns of care data from a multi-site CDC study as well as from SEER Patterns of Care data on prostate cancer. She has been the recruitment core lead for the RESPOND Study (C. Haiman, PI) that has already recruited 12,500 African American men with prostate cancer nationwide, has obtained 7,000 saliva/germline DNA samples and 2,800 tumor tissue samples. In addition she has led and participated in studies of thyroid cancer, adolescent and young adult cancer, as well as breast and ovarian cancer. Currently she is also involved with studies regarding genetic testing for cancer patients and how this information is relayed to relatives.

• UCLA: Delta Omega Public Health Honor Society, 1986
• UCLA: University of California National Institutes of Health Trainee,, 1982
   – 1985

• Carleton College, Northfield, MN — BA — 06/70 — Biology
• Georgetown University, Washington, DC — MA — 6/74 — Demography
• University of California, Los Angeles — Ph.D. — 6/87 — Public Health, Epidemiology

• Risk stratified survivorship care pathways for early-onset colorectal cancer
  NCI · Mar 21, 2023 – Feb 29, 2028 · Role: Los Angeles Subcontract PI, co-investigator
• Multilevel Mechanisms of Racial/Ethnic Disparities in Early-Stage Lung Cancer Treatment: The Role of patient, provider, and geographical-level Factors
  ACS · Jan 1, 2023 – Dec 31, 2027 · Role: Co-investigator
• A Registry Based Study of patterns of Use of Targeted Therapies for Metastatic Cancers in Diverse Populations
  NCI · May 1, 2021 – Oct 31, 2025 · Role: Los Angeles Subcontract PI, co-investigator
• 10-year Comparative Effectiveness and Harms of Treatments for Prostate Cancer
  NCI · Apr 1, 2021 – Mar 31, 2025 · Role: Co-Investigator, Los Angeles Subcontract PI
• Project Milestones: Young Adult Cancer Survivorship
  NCI · Jan 1, 2021 – Dec 31, 2025 · Role: Co-investigator, USC subcontract PI
• Prostate Cancer Comparative Outcomes of New Conceptual Paradigms for Treatment
  PCORI · Nov 1, 2020 – Oct 31, 2024 · Role: Los Angeles Subcontract PI, Co-PI
• A population based virtual solution to reduce gaps in genetic risk evaluation and management in families at high risk for hereditary cancer syndromes: the Georgia/California gene link trial
  NCI · Sep 1, 2020 – Aug 31, 2025 · Role: Los Angeles Subcontract PI, co-investigator
• Gaps in Genetic Risk Prevention in Breast Cancer Patients and Their Family
  ACS · Sep 1, 2020 – Aug 31, 2024 · Role: Los Angeles Subcontract PI, Co-investigator
• Research on Prostate Cancer in Men of African Ancestry: Defining the Roles of Genetics, Immunity and Stress (RESPOND)
  NCI/NIMHD/PCF · Jul 1, 2019 – Jun 30, 2024 · Role: Co-investigator, Recruitment Core Lead

• Cancer outcomes research
• Prostate cancer
• Breast cancer
• Genetic testing
• Cancer registries
• Survey methods
• Health disparities

• Prostate cancer study shows racial disparity in function after surgery

• Matsuo, Koji
• Haiman, Christopher
• Gill, Inderbir
• Unger, Jennifer
• Freyer, David
• Lenz, Heinz-Josef